These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 11850217

  • 1. Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy.
    Ragaz J.
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):133-41. PubMed ID: 11850217
    [Abstract] [Full Text] [Related]

  • 2. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A, Howell SJ, Clarke R, Anderson E.
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [Abstract] [Full Text] [Related]

  • 3. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS.
    Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
    [Abstract] [Full Text] [Related]

  • 4. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE.
    Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
    [Abstract] [Full Text] [Related]

  • 5. Are aromatase inhibitors superior to antiestrogens?
    Howell A, Buzdar A.
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
    [Abstract] [Full Text] [Related]

  • 6. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ, Dawson C, Lawrence DH, Bliss JM.
    Cochrane Database Syst Rev; 2007 Jan 24; (1):CD003370. PubMed ID: 17253488
    [Abstract] [Full Text] [Related]

  • 7. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J.
    Clin Ther; 2005 Nov 24; 27(11):1671-84. PubMed ID: 16368441
    [Abstract] [Full Text] [Related]

  • 8. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C.
    Am J Clin Oncol; 2003 Aug 24; 26(4):S9-16. PubMed ID: 12902872
    [Abstract] [Full Text] [Related]

  • 9. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P, Frassoldati A.
    Breast J; 2007 Aug 24; 13(1):28-35. PubMed ID: 17214790
    [Abstract] [Full Text] [Related]

  • 10. Safety of aromatase inhibitors in the adjuvant setting.
    Perez EA.
    Breast Cancer Res Treat; 2007 Aug 24; 105 Suppl 1(Suppl 1):75-89. PubMed ID: 17912638
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
    Carlson RW, Hudis CA, Pritchard KI, National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines in Oncology, American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors, St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer.
    J Natl Compr Canc Netw; 2006 Nov 24; 4(10):971-9. PubMed ID: 17112447
    [Abstract] [Full Text] [Related]

  • 12. Future use of selective estrogen receptor modulators and aromatase inhibitors.
    Howell A.
    Clin Cancer Res; 2001 Dec 24; 7(12 Suppl):4402s-4410s; discussion 4411s-4412s. PubMed ID: 11916232
    [Abstract] [Full Text] [Related]

  • 13. Aromatase inhibitors and breast cancer.
    Miller WR.
    Minerva Endocrinol; 2006 Mar 24; 31(1):27-46. PubMed ID: 16498362
    [Abstract] [Full Text] [Related]

  • 14. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G.
    Cancer; 2004 Oct 01; 101(7):1482-9. PubMed ID: 15378476
    [Abstract] [Full Text] [Related]

  • 15. Preliminary data from ongoing adjuvant aromatase inhibitor trials.
    Goss PE.
    Clin Cancer Res; 2001 Dec 01; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s. PubMed ID: 11916231
    [Abstract] [Full Text] [Related]

  • 16. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R.
    Eur J Surg Oncol; 2008 Jul 01; 34(7):746-55. PubMed ID: 18296017
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
    Nabholtz JM, Gligorov J.
    Drug Saf; 2006 Jul 01; 29(9):785-801. PubMed ID: 16944964
    [Abstract] [Full Text] [Related]

  • 20. A summary of second-line randomized studies of aromatase inhibitors.
    Buzdar AU.
    J Steroid Biochem Mol Biol; 2001 Dec 01; 79(1-5):109-14. PubMed ID: 11850214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.